Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: First-line Replacement Maintenance of Envafolimab in Advanced NSCLC [Phase 2]
A Phase 2 trial evaluating first-line replacement maintenance with Envafolimab in advanced non-small cell lung cancer (NSCLC) is ongoing, wi…
-
CLINICAL_TRIALS trial_result · 2022-07-15Clinical Trial Update: Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation [Phase 2]
Phase 2 trial evaluating sintilimab with anlotinib for perioperative non-small cell lung cancer guided by minimal residual disease assessmen…
-
CLINICAL_TRIALS trial_result · 2022-07-13Clinical Trial Update: Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin [Phase 3]
Phase 3 trial update comparing Tavocept to placebo in combination therapy for newly diagnosed or relapsed advanced non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2022-07-13Clinical Trial Update: Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
A completed real-world study from Sweden examining sequencing of ALK tyrosine kinase inhibitors and therapeutic outcomes in ALK-positive non…
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating bevacizumab and erlotinib in advanced non-small cell lung cancer has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE） [Phase 2]
A Phase 2 trial investigating neoadjuvant sintilimab with chemotherapy for resectable non-small cell lung cancer (NSCLC).
-
CLINICAL_TRIALS trial_result · 2022-07-11Clinical Trial Update: An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib [Phase 2]
Open-label Phase 2 trial of sotorasib in KRAS G12C-mutant non-small cell lung cancer with a translational study to identify acquired resista…
-
CLINICAL_TRIALS trial_result · 2022-07-07Clinical Trial Update: A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC [Phase 2]
Phase 2 study investigating famitinib in combination with HS-10296 for EGFR-mutant non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2022-07-07Clinical Trial Update: Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC [Phase 2]
Phase 2 trial updating a combination of recombinant human endostatin with PD-1 antibody and first-line chemotherapy for driver gene negative…
-
CLINICAL_TRIALS trial_result · 2022-07-06Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression [Phase 2]
Phase 2 trial evaluating HLX07 in nonsquamous non-small cell lung cancer with high EGFR expression (status unknown).
-
CLINICAL_TRIALS trial_result · 2022-06-30Clinical Trial Update: E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C [Phase 1, Phase 2]
Phase 1/2 study evaluating an EGFR tyrosine kinase inhibitor in combination with EGF receptor pathway targeting in EGFR-mutant non-small cel…
-
CLINICAL_TRIALS trial_result · 2022-06-29Clinical Trial Update: Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Navarixin in combination with pembrolizumab in adults with selected advanced/metastatic …
-
CLINICAL_TRIALS trial_result · 2022-06-29Clinical Trial Update: M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing M7824 (bintrafusp alfa) to pembrolizumab as first-line treatment in PD-L1-expressing advanced non-small cell lung ca…
-
CLINICAL_TRIALS trial_result · 2022-06-28Clinical Trial Update: Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC [Phase 1, Phase 2]
Phase 1/2 trial evaluating nivolumab combined with anlotinib as re-challenge therapy in advanced non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2022-06-28Clinical Trial Update: Phase II Trial of Continuation Therapy in Advanced NSCLC [Phase 2]
Phase II trial update on continuation therapy for advanced non-small cell lung cancer has completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-06-28Clinical Trial Update: Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 trial update for HS-10376 in advanced non-small cell lung cancer (NSCLC).
-
CLINICAL_TRIALS trial_result · 2022-06-27Clinical Trial Update: Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial updating docetaxel with or without PI-88 in stage IIIB/IV non-small cell lung cancer completed.
-
CLINICAL_TRIALS trial_result · 2022-06-27Clinical Trial Update: Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC) [Phase 2]
Phase 2 trial of PI-88 with docetaxel in advanced non-small-cell lung cancer completed.
-
CLINICAL_TRIALS trial_result · 2022-06-24Clinical Trial Update: Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE) [Phase 2]
Phase 2 trial update evaluating neoadjuvant furmonertinib with cisplatin/pemetrexed in EGFR-mutated resectable NSCLC (stages IIIA-IIIB).
-
CLINICAL_TRIALS trial_result · 2022-06-23Clinical Trial Update: Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies [Phase 1, Phase 2]
Phase 1/2 trial evaluating avelumab plus chemotherapy with or without other anti-cancer immunotherapy agents in advanced malignancies (termi…
-
FDA approval · 2022-06-22FDA Approved: PEMETREXED — Original Application (Hospira, Inc.)
FDA approved Hospira, Inc.'s original application for pemetrexed (injectable), authorizing a generic pemetrexed product with the established…
-
CLINICAL_TRIALS trial_result · 2022-06-22Clinical Trial Update: Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of Sym015 (anti-MET) in advanced solid tumors, including MET-amplified/non-small cell lung cancer, completed with posted res…
-
CLINICAL_TRIALS trial_result · 2022-06-22Clinical Trial Update: TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing TAB008 to Avastin in EGFR wild-type non-squamous non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2022-06-22Clinical Trial Update: Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative [Phase 1, Phase 2]
Clinical trial update for Ningetinib (CT053PTSA) plus Gefitinib in stage IIIB/IV non-small cell lung cancer with EGFR mutation and T790M neg…
-
CLINICAL_TRIALS trial_result · 2022-06-22Clinical Trial Update: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer [Phase 1, Phase 2]
This clinical trial update reports results from a Phase 1/2 study of erlotinib hydrochloride combined with onalespib lactate in patients wit…